Most Americans who want Zepbound can’t get their insurance to pay for it, and the reasons range from federal law to employer cost concerns to the way drug pricing works behind the scenes. Only 18% of large employers covered GLP-1 medications for weight loss in 2024, and Medicare is legally prohibited from covering them at all. Understanding why your specific plan says no is the first step toward figuring out your options.
Medicare Can’t Cover It by Law
If you’re on Medicare, the denial isn’t a judgment call by your plan. It’s federal statute. The Social Security Act explicitly excludes “agents when used for anorexia, weight loss, or weight gain” from the definition of a covered Part D drug. That language has been in the law for decades, written long before medications like Zepbound existed. Congress would need to change the statute for Medicare to start covering weight loss drugs, and while bills have been introduced, none have passed yet.
This matters because Zepbound and its chemically identical counterpart Mounjaro contain the same active ingredient, tirzepatide. Mounjaro is approved for type 2 diabetes and is generally covered by Medicare. Zepbound is approved specifically for weight management. Same molecule, different FDA indication, completely different coverage outcome.
Most Employer Plans Exclude Weight Loss Drugs
Even if you have commercial insurance through your job, your employer likely chose not to cover Zepbound. A 2024 survey published in Health Affairs found that only 18% of large firms covered GLP-1 medications for weight loss. Among the biggest companies (5,000 or more employees), that number rose to 28%, but it still left the majority of workers without coverage. Of the employers that didn’t cover these drugs, 62% said they were “not likely” to start covering them within the next year.
The math is straightforward. Zepbound’s list price runs roughly $1,000 per month, and the medication is designed to be taken long-term. Employers set their benefits budgets annually and weigh drug costs against premiums. Covering a $12,000-per-year medication for a potentially large portion of their workforce would raise plan costs significantly. Many employers have concluded that the expense isn’t sustainable at current prices.
How Pharmacy Benefit Managers Shape Your Formulary
Your insurance plan doesn’t build its drug list alone. Pharmacy benefit managers, known as PBMs, negotiate with drug manufacturers on behalf of insurers and employers. They decide which medications get “preferred” placement on a formulary, and those decisions are heavily influenced by rebates.
Here’s how it works: a drug manufacturer offers a PBM a rebate (essentially a discount paid after the sale) in exchange for favorable formulary placement. PBMs may actually favor higher-priced drugs that come with larger rebates over lower-priced alternatives, because those rebates help offset overall plan costs and keep premiums down. If a manufacturer doesn’t offer competitive rebates, the PBM may exclude the drug entirely or place it on a high-cost tier that requires substantial copays or prior authorization. This system means your coverage decision was partly made in a negotiation you never saw.
You Don’t Meet the Clinical Criteria
Even plans that do cover Zepbound set strict eligibility requirements that mirror or exceed the FDA’s approval criteria. The FDA approved Zepbound for adults with a BMI of 30 or higher, or a BMI of 27 or higher when accompanied by at least one weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes, sleep apnea, or cardiovascular disease.
Many insurers layer additional requirements on top of the FDA label. A common one is “step therapy,” meaning you must first try and fail a cheaper weight loss medication before the plan will authorize Zepbound. Some plans also require documentation that you’ve participated in a structured diet and exercise program. If your doctor prescribed Zepbound without checking these boxes in the paperwork, the claim gets denied even though you might technically qualify.
What a Successful Appeal Looks Like
A denial isn’t always the final answer. Insurance appeals for Zepbound require specific clinical documentation, and understanding what reviewers look for can improve your chances. Based on real appeal decisions, the key elements include:
- BMI documentation: A recorded BMI of 30 or above, or 27 or above with a diagnosed weight-related condition like coronary heart disease, high blood pressure, sleep apnea, polycystic ovarian syndrome, prediabetes, or fatty liver disease.
- Step therapy evidence: Proof that you tried a lower-cost weight loss medication first and it didn’t work, or documentation explaining why that medication is contraindicated for you.
- For renewals: Evidence of at least 5% weight loss from your starting weight, or measurable improvement in related health markers like blood sugar or blood pressure, even if the scale hasn’t moved as much.
Your prescribing doctor typically handles the appeal, but you can ask them what documentation they’re submitting and whether it addresses the insurer’s specific denial reason. The denial letter itself will state the reason, and a targeted appeal that directly counters that reason has a better chance than a generic letter.
Options When Coverage Isn’t Coming
Eli Lilly, the manufacturer, offers savings programs that can reduce out-of-pocket costs for commercially insured patients, though the terms and availability change frequently. It’s worth checking Lilly’s Zepbound website directly for current offers, as some programs have brought monthly costs down to $199 or less for eligible patients.
Zepbound’s list price at the lowest dose starts around $300 per month without insurance, though higher doses cost more, approaching $1,069 for a month’s supply. Compounded versions of tirzepatide have been available through some pharmacies at lower prices, though the FDA has been scrutinizing the compounding market closely.
If your employer doesn’t cover weight loss medications and you work at a company large enough to have a benefits department, it’s worth raising the issue during open enrollment season. Employers make coverage decisions annually, and employee demand is one factor that influences those choices. The 18% coverage rate in 2024 was higher than the year before, suggesting that employer adoption is growing, just slowly.